Bu Tingcheng, Gu Wendong, Shao Yingjie
Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China.
Discov Oncol. 2025 Jul 15;16(1):1334. doi: 10.1007/s12672-025-03189-5.
Long noncoding RNAs (lncRNAs), defined as noncoding transcripts exceeding 200 nucleotides without protein-coding potential, have been increasingly recognized for encoding polipeptides or proteinsimplicated in the regulation of malignant tumor initiation, progression, and prognosis. Among them, small nucleolar RNA host gene 29 (SNHG29) has attracted increasing attention because of its aberrant expression across diverse malignancies. This report reviews the latest research regarding its expression patterns, regulatory functions, and involved signaling pathways. This review synthesizes current insights into the contributions of SNHG29 to oncogenic processes, including cell proliferation, migration, epithelial‒mesenchymal transition, chemoresistance, and immunosuppression. Furthermore, evidence indicates that SNHG29 functions as a competing endogenous RNA (ceRNA), modulating tumor progression via the miRNA‒mRNA axis and signaling pathways such as the ATR‒Chk1, PI3K‒AKT, and Wnt‒β-catenin pathways. Cumulative data position SNHG29 as a promising diagnostic and prognostic biomarker, as well as a potential molecular target for therapeutic intervention in various malignancies.
长链非编码RNA(lncRNAs)被定义为长度超过200个核苷酸且无蛋白质编码潜能的非编码转录本,其在编码参与恶性肿瘤起始、进展和预后调控的多肽或蛋白质方面的作用已得到越来越多的认可。其中,小核仁RNA宿主基因29(SNHG29)因其在多种恶性肿瘤中的异常表达而受到越来越多的关注。本报告综述了关于其表达模式、调控功能及相关信号通路的最新研究。本综述综合了目前对SNHG29在致癌过程中作用的见解,包括细胞增殖、迁移、上皮-间质转化、化疗耐药和免疫抑制。此外,有证据表明SNHG29作为一种竞争性内源性RNA(ceRNA),通过miRNA-mRNA轴以及ATR-Chk1、PI3K-AKT和Wnt-β-连环蛋白等信号通路调节肿瘤进展。累积数据表明SNHG29是一种有前景的诊断和预后生物标志物,也是各种恶性肿瘤治疗干预的潜在分子靶点。